Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
Oppenheimer has reiterated its Buy rating for Tarsus Pharmaceuticals (TARS.US), maintaining a price target of $100. This indicates the firm's continued confidence in the company's financial prospects and stock performance.
Tarsus Pharmaceuticals, Inc. (TARS) stock price, news, quote and history
Tarsus Pharmaceuticals, Inc. (TARS) experienced a slight decline of 4.01% in its stock price, closing at $75.46. The company, a commercial-stage biopharmaceutical firm, focuses on eye care therapeutics, including its product XDEMVY for demodex blepharitis, and has other candidates in development for ocular rosacea and Lyme disease. Analysts maintain a "Buy" rating with an average target price of $99.50.
Tarsus Pharmaceuticals, Inc. (TARS) Stock Price, News, Quote & History
Tarsus Pharmaceuticals, Inc. (TARS) stock closed at $75.46, down 4.01% on October 1st, 2026, with after-hours trading showing a slight increase. The company focuses on developing therapeutic candidates for eye care, including XDEMVY for Demodex blepharitis, and has several other candidates in clinical trials. Tarsus has shown strong 1-year, 3-year, and 5-year returns, outperforming the S&P 500.
Pyott David E I Executes Options in Tarsus Pharmaceuticals, Retains 9,575 Shares
Pyott David E I, a director of Tarsus Pharmaceuticals (NASDAQ: TARS), recently exercised options resulting in a holding of 9,575 shares, which represents approximately 2.1% of his total shares in the company. This transaction also accounted for about 24.9% of his previous derivative securities holdings. The option exercise took place on September 15, 2026.
Tarsus Pharmaceuticals (TARS) director adds 201 shares through RSU conversion
Tarsus Pharmaceuticals director David E. I. Pyott converted 201 Restricted Stock Units (RSUs) into common shares on September 15, 2026, which are now held indirectly through his trust. Following this transaction, his trust holds 9,575 common shares, and he retains 605 RSUs that will vest in equal installments through June 2027. This transaction, reported via a Form 4 SEC filing, indicates a neutral impact and sentiment.
Tarsus Pharmaceuticals (TARS) director sells shares under preset plan
Tarsus Pharmaceuticals director William J. Link sold 12,500 common shares at weighted average prices around $79 under a pre-planned Rule 10b5-1 trading plan. This transaction followed the exercise of 201 Restricted Stock Units (RSUs) into common stock on September 15, 2026. After these sales, Link holds 94,487 common shares and 605 RSUs.
Nearly $1M Tarsus (NASDAQ: TARS) insider share sale planned by a company director
Tarsus Pharmaceuticals, Inc. (TARS) director J. Link plans to sell 12,500 shares of common stock, valued at approximately $979,745.36, through Merrill Lynch on or about September 15, 2026. These shares were acquired via a stock option exercise in January 2017. This transaction was disclosed in a Rule 144 notice, which outlines conditions for reselling restricted or insider-held shares to the public.
Tarsus Pharmaceuticals Finalizes Acquisition of Alkeus Pharmaceuticals with $270M Cash and Stock Deal
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals for an initial payment of $270 million in cash and 2,908,692 shares of Tarsus common stock. The deal also includes potential milestone payments of up to $350 million tied to regulatory approval and the first U.S. sale of an Alkeus product, along with tiered revenue sharing. Alkeus will continue to operate as a wholly-owned subsidiary of Tarsus.
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, adding worldwide rights to ALK-001, an investigational drug for Stargardt disease. This acquisition strengthens Tarsus's pipeline in eye care and positions ALK-001 as a potential foundational medicine for the blinding disease, which currently lacks FDA-approved treatments. Topline data for the Phase 3 NORTHSTAR trial of ALK-001 is expected in 2029.
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com
Jefferies has increased its price target for Tarsus Pharmaceuticals (NASDAQ:TARS) to $105 from $88, maintaining a Buy rating. This adjustment follows Tarsus Pharmaceuticals' raised Xdemvy 2026 guidance and strong third-quarter prescription data. The firm also noted the strategic acquisitions of Alkeus and iRenix, which add significant late-stage assets to Tarsus's pipeline, bolstering its long-term valuation despite a recent earnings per share miss.
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, adding ALK-001, an investigational oral therapy for Stargardt disease, to its pipeline. This acquisition aims to strengthen Tarsus's position in eyecare, particularly with ALK-001's potential to treat a condition with no FDA-approved therapies, and topline data for its phase 3 trial expected in 2029. The deal involved an upfront payment of $450 million and potential milestones up to $350 million.
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD
Tarsus Pharmaceuticals Inc. stock has reached an all-time high of $85.29, surging nearly 16% in the past week and trading within 1% of its 52-week high, with a 47.84% appreciation over the past year. Despite impressive revenue growth of 105% over the last twelve months, InvestingPro Tips indicate the stock is overbought and analysts do not expect profitability this year. The company recently reported Q2 2026 net product sales of $173.9 million, exceeding expectations, and raised full-year sales guidance for its eye drug, XDEMVY.
Tarsus Pharmaceuticals Acquires Alkeus, Gildeuretinol for Stargardt Disease
Tarsus Pharmaceuticals has acquired Alkeus Pharmaceuticals and its lead asset, gildeuretinol (ALK-001), an investigational drug for Stargardt disease. This acquisition expands Tarsus's ophthalmology portfolio, leveraging its existing infrastructure in eye care. The value of the deal hinges on the Phase 3 clinical trial readout for gildeuretinol, which targets the underlying biology of the disease.
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com
Tarsus Pharmaceuticals Inc. has reached an all-time stock high of $85.29, surging nearly 16% in the past week and appreciating by 47.84% over the last year. Despite impressive revenue growth of 105% in the last twelve months, InvestingPro Tips indicate the stock is overbought and profitability is not expected this year. The company recently reported Q2 2026 net product sales of $173.9 million, exceeding expectations, and raised its full-year sales guidance for its eye drug XDEMVY, even though it reported a wider-than-anticipated loss per share.
Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals
Tarsus Pharmaceuticals announced the completion of its acquisition of Alkeus Pharmaceuticals. The acquisition will allow Tarsus to expand its portfolio, particularly in retinal disease treatment. This move aims to strengthen Tarsus's position in the pharmaceutical market.
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com
Tarsus Pharmaceuticals (NASDAQ: TARS) has reached an all-time stock high of $85.29, reflecting robust performance with a 47.84% appreciation over the past year and 105% revenue growth. Despite trading in overbought territory and analysts not expecting profitability this year, investor confidence remains high, bolstered by strong Q2 2026 sales and a raised full-year guidance for its eye drug XDEMVY. The biotech sector itself is experiencing dynamic activity, with a significant increase in global funding.
Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition
Tarsus Pharmaceuticals' shares increased after the company completed its acquisition of Alkeus Pharmaceuticals. The acquisition, initially announced in early August, is valued at approximately $800 million. Tarsus Pharmaceuticals is a biopharmaceutical company specializing in eye care, with its lead product XDEMVY targeting Demodex blepharitis.
Tarsus Pharmaceuticals Completes Acquisition of Alkeus, Adds Gildeuretinol for Stargardt Disease to Pipeline
Tarsus Pharmaceuticals has successfully acquired Alkeus Pharmaceuticals, securing worldwide rights to gildeuretinol (ALK-001), a Phase 3 investigational oral treatment for Stargardt disease, a blinding condition with no FDA-approved therapies. This acquisition aims to strengthen Tarsus's position in eye care and advance the development of ALK-001, which has received Breakthrough Therapy and Orphan Drug designations. Topline data from the NORTHSTAR Phase 3 trial are anticipated in 2029.
Tarsus to Participate in Upcoming Investor Conferences
Tarsus Pharmaceuticals, Inc. announced its management will participate in two upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 8th and the H.C. Wainwright 28th Annual Global Investment Conference on September 15th. The company will host a fireside chat at the latter event. Webcasts and replays will be available on the Tarsus website.
After $3.8M sale, Tarsus (TARS) ex-officer plans more selling
A former officer of Tarsus Pharmaceuticals, Inc. (TARS), Aziz A. Mottiwala, plans to sell 81,332 shares of common stock valued at $5.8 million, following a recent sale of 53,043 shares for $3.8 million. This information comes from a Rule 144 notice filed with the SEC, indicating the shares originate from a stock option exercise. The company currently has 43,882,996 shares of common stock outstanding.
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 3.82 Million in Common Stocks
An insider at Tarsus Pharmaceuticals (TARS.US) has proposed to sell 3.82 million common stocks, as disclosed in a recent Form 144 filing. This significant proposed sale by an insider may be of interest to current and potential investors monitoring the company's stock activity.
Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares
A former officer of Tarsus Pharmaceuticals, Aziz A. Mottiwala, plans to sell 53,043 shares of common stock, valued at approximately $3.8 million. The sale is connected to a stock option exercise and will be handled by Fidelity Brokerage Services LLC. This information was disclosed in a Form 144 SEC filing.
TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS
TimesSquare Capital Management LLC has acquired a new stake of $23.25 million in Tarsus Pharmaceuticals, Inc., purchasing 369,377 shares, representing a 0.86% ownership. Institutional investors now collectively own approximately 90.01% of the company, which holds a "Moderate Buy" consensus rating from analysts with an average price target of $90.50. Despite reporting quarterly revenue ahead of estimates at $173.91 million, Tarsus Pharmaceuticals experienced a wider-than-expected loss of $0.43 per share.
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention?
Tarsus Pharmaceuticals (TARS) shares have seen positive movement following its Q2 2026 earnings report, which indicated higher revenue, a reduced net loss, and an increased full-year sales outlook for XDEMVY. The company is currently considered 25% undervalued with a fair value of $94.11 per share, driven by anticipated revenue expansion and margin improvements, alongside pipeline diversification efforts. Investors are encouraged to analyze the company's financial data and consider potential risks associated with its reliance on XDEMVY and ongoing high costs.
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention?
Tarsus Pharmaceuticals (TARS) shares have recently gained investor attention following its strong Q2 2026 earnings report, which showed increased revenue and a higher sales outlook for XDEMVY. Despite a year-to-date share price decline, the stock has seen positive short-term returns. Analysts suggest Tarsus Pharmaceuticals is currently undervalued by 25%, with a fair value of $94.11 per share, driven by anticipated revenue growth and pipeline expansion.
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next
Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong Q2 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increased confidence in XDEMVY's commercial trajectory supports the company's near-term revenue, though risks related to single-product dependence and high SG&A remain. Analysts are now evaluating whether this guidance shift reinforces bullish views or prompts a re-evaluation of risks.
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next
Tarsus Pharmaceuticals (TARS) saw its stock rise 6.8% after reporting strong Q2 2026 results, with revenue up and net loss narrowing. The company also significantly raised its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million, reflecting increased confidence in the product's market trajectory. This revised guidance reinforces XDEMVY's central role in the company's growth but highlights risks associated with single-product dependence and high SG&A spend.
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next
Tarsus Pharmaceuticals (TARS) saw its stock rise by 6.8% after reporting strong second-quarter 2026 results and raising its 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. This increase signals management's confidence in XDEMVY's commercial trajectory, though the company still faces risks associated with single-product dependence and high SG&A costs. Analysts project significant revenue and earnings growth for Tarsus by 2029, with some anticipating a fair value upside.
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Moderate Buy" by Brokerages
Tarsus Pharmaceuticals (NASDAQ:TARS) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $90.50, significantly higher than its current share price of $69.20. The company recently reported quarterly revenue of $173.91 million, surpassing estimates, but its loss per share of $0.43 was wider than expected. Insiders have sold a notable amount of shares, while institutional investors hold a substantial 90.01% of the company's stock.
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak
Tarsus Pharmaceuticals (TARS) stock has shown a significant 3-year return but appears undervalued according to broader valuation checks. The company's P/S ratio of 5.0x is in line with the industry average and below its peer group, suggesting attractive pricing despite ongoing losses. News of acquisitions and pipeline expansion could support future cash flow, but investors need to consider execution risks and funding needs.
Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus
Janus Henderson Group Ltd. has disclosed a 6.5% beneficial ownership stake in Tarsus Pharmaceuticals, Inc., totaling 2,808,796 shares of common stock. This ownership is held through its affiliated asset managers via Managed Portfolios, where they exercise investment and voting discretion. The filing indicates shared voting and dispositive power for these shares, with no individual Managed Portfolio owning more than 5% of Tarsus common stock.
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
Mizuho Securities analyst Graig Suvannavejh has reiterated a Buy rating for Tarsus Pharmaceuticals (TARS.US), maintaining a target price of $100. According to TipRanks data, Suvannavejh has a 52.0% success rate and a 24.3% average return over the past year. The information is provided for informational purposes and does not constitute an investment recommendation.
Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating
Oppenheimer has increased its price target for Tarsus Pharmaceuticals (TARS) to $100 from $97, while maintaining an "Outperform" rating on the stock. This adjustment comes amidst recent company activities including an acquisition agreement with Alkeus Pharmaceuticals and Q2 2026 earnings results. Mizuho also recently adjusted its price target for Tarsus Pharmaceuticals.
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
Tarsus Pharmaceuticals announced an oversubscribed $125.0 million private placement equity financing through a PIPE agreement. The financing includes participation from existing investors of Alkeus Pharmaceuticals, which Tarsus is acquiring, as well as new and existing Tarsus investors. The proceeds are intended to fund clinical development, commercial activities, and general corporate purposes, with the closing expected on August 7, 2026.
Tarsus Pharmaceuticals (TARS) Lifts XDEMVY Guidance Following Earnings But Is The Stock Already Priced In
Tarsus Pharmaceuticals (TARS) reported strong Q2 2026 revenues of $173.91 million and raised its full-year XDEMVY sales guidance, suggesting significant commercial momentum. Despite recent stock gains, Simply Wall St's analysis indicates the stock might still be 31.2% undervalued with a fair value of $94.11 per share. However, this positive outlook depends heavily on continued XDEMVY performance and its impact on long-term profitability.
Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus
Tarsus Pharmaceuticals (TARS) saw its stock rise by 9.7% after reporting strong Q2 revenue of US$173.91 million and raising its full-year 2026 XDEMVY net product sales guidance to US$685 million–US$705 million. The company also announced the acquisition of Alkeus Pharmaceuticals, adding a late-stage asset for Stargardt disease to its ophthalmology pipeline, diversifying beyond its single-drug dependency. While the raised guidance reinforces short-term prescription momentum, analysts note continued risks related to payer pressure, reimbursement, and the costs associated with the new acquisition.
Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus
Tarsus Pharmaceuticals (TARS) saw a 9.7% stock increase after reporting strong Q2 revenue and raising its full-year 2026 XDEMVY sales guidance to US$685 million–US$705 million. The company also acquired Alkeus Pharmaceuticals, adding gildeuretinol for Stargardt disease to its ophthalmology pipeline, which diversifies its assets but also brings additional R&D costs. Despite the positive outlook for XDEMVY and the acquisition, the company still faces risks related to its reliance on a single product and potential payer pressure on margins.
Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results
Tarsus Pharmaceuticals (NASDAQ:TARS) reported its latest earnings, missing analyst expectations on EPS with a loss of $0.43 per share against an estimated loss of $0.19, despite exceeding revenue forecasts with $173.91 million. The company announced a significant acquisition of Alkeus Pharmaceuticals for up to $800 million, expanding its pipeline into Stargardt disease therapy. While XDEMVY sales showed strong growth and guidance was raised, increased R&D spending and acquisition costs could delay projected profitability.
Tarsus Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TARS) 2026-08-06
Tarsus Pharmaceuticals, Inc. (TARS) published its Q2 2026 earnings call presentation on August 6, 2026. The company reported an EPS of -$0.43, missing estimates by $0.23, while revenue reached $173.91M, beating expectations by $4.40M and showing a 69.41% year-over-year increase. This article includes the slide deck from the earnings call.
Press Release: Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
Tarsus Pharmaceuticals announced an oversubscribed private placement equity financing of $125.0 million. The financing is led by new and existing institutional investors, including Fidelity Management & Research Company LLC, RA Capital Management, and Eventide Asset Management. The proceeds are intended to fund the continued clinical development and commercialization of TP-03 and for other general corporate purposes.
Latham & Watkins Advises Alkeus Pharmaceuticals on Acquisition by Tarsus Pharmaceuticals
Latham & Watkins LLP advised Alkeus Pharmaceuticals on its acquisition by Tarsus Pharmaceuticals, Inc. The deal, announced on July 31, 2026, involves Tarsus acquiring Alkeus, a privately held retinal disease-focused biotechnology company developing gildeuretinol (ALK-001) for Stargardt disease. A comprehensive legal team from Latham & Watkins, led by partners Scott Shean, Andrew Clark, and Shannon Cheng, provided counsel across various specializations for the transaction.
Tarsus Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $93.57, Implies 53% Upside
The average 12-month price target for Tarsus Pharmaceuticals, Inc. stock has been slightly reduced from $94.22 to $93.57 by seven analysts, with forecasts ranging from $84 to $104 per share. This new target implies a potential upside of approximately 53% from its closing price on August 5. The consensus rating among these analysts remains a "Buy."
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
Tarsus Pharmaceuticals announced an oversubscribed $125.0 million private placement equity financing through a PIPE agreement. The financing includes participation from existing investors of Alkeus Pharmaceuticals, which Tarsus is in the process of acquiring, as well as new and existing Tarsus investors. The proceeds will fund clinical development, commercial activities, and general corporate purposes.
Tarsus to purchase Alkeus Pharmaceuticals
Tarsus Pharmaceuticals plans to acquire Alkeus Pharmaceuticals, including its late-stage investigational therapy for Stargardt disease, gildeuretinol acetate (ALK-001). The deal involves an estimated $450 million upfront consideration in cash and stock, plus potential future milestones and royalties. ALK-001 has received multiple FDA designations and shown promising results in clinical trials for slowing retinal lesion growth in Stargardt disease.
Tarsus Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $93.57, Implies 53% Upside
Tarsus Pharmaceuticals, Inc.'s average 12-month stock price target has been lowered slightly from $94.22 to $93.57 by 7 analysts, with individual forecasts ranging from $84 to $104 per share. Based on the August 5th closing price, this updated target suggests a potential upside of approximately 53%. The consensus rating from all 7 analysts remains a "Buy."
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) reported a Q2 loss of $0.43 per share, exceeding the Zacks Consensus Estimate of a $0.21 loss, but surpassed revenue expectations with $173.91 million. Despite consistently beating revenue estimates, the stock has underperformed the S&P 500 year-to-date, and its current Zacks Rank #4 (Sell) suggests potential future underperformance. The company's earnings outlook and industry trends will be key factors for investors moving forward.
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals announced its plan to acquire Alkeus Pharmaceuticals in a deal valued at up to $800 million. This acquisition will expand Tarsus's eye disease pipeline by adding an experimental oral therapy for a rare inherited retinal disorder for which there is currently no approved U.S. treatment. The deal is structured as a cash-and-stock transaction.
Tarsus to Raise About $125M, Selling Stock at $56 a Share
Tarsus Pharmaceuticals announced an oversubscribed private placement (PIPE) expected to generate approximately $125.0 million in gross proceeds. The company will sell 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants for 133,625 shares. The financing includes participation from both existing and new institutional investors, with closing anticipated on August 7, 2026.
Tarsus pays $450M for Alkeus and its ph. 3 retinal disease drug
Tarsus Pharmaceuticals has acquired Alkeus Pharmaceuticals for $450 million, securing gildeuretinol, a phase 3 retinal disease drug for Stargardt disease. The deal, comprising cash and stock, also includes potential milestone payments and aims to expand Tarsus's ophthalmology portfolio. Gildeuretinol, if approved, could address a significant unmet medical need for Stargardt disease, an inherited vision-loss condition.
Tarsus to report Q2 2026 results on August 6
Tarsus Pharmaceuticals, Inc. will host a live webcast on August 6, 2026, to report its second-quarter 2026 financial results and provide a corporate update. The event is scheduled for 5:00 a.m. PT / 8:00 a.m. ET, with a recording available for 90 days. The company will discuss its operational and financial performance, including advancements in its pipeline such as FDA-approved XDEMVY and Phase 2 candidates TP-04 and TP-05.
